Presented at the 2006 American Association of the Study for Liver Diseases, Boston, MA, 27–30 October 2006.
Reduced Mortality with Right-Lobe Living Donor Compared to Deceased-Donor Liver Transplantation When Analyzed from the Time of Listing
Article first published online: 26 MAR 2007
American Journal of Transplantation
Volume 7, Issue 4, pages 998–1002, April 2007
How to Cite
Shah, S. A., Levy, G. A., Greig, P. D., Smith, R., McGilvray, I. D., Lilly, L. B., Girgrah, N., Cattral, M. S. and Grant, D. R. (2007), Reduced Mortality with Right-Lobe Living Donor Compared to Deceased-Donor Liver Transplantation When Analyzed from the Time of Listing. American Journal of Transplantation, 7: 998–1002. doi: 10.1111/j.1600-6143.2006.01692.x
- Issue published online: 26 MAR 2007
- Article first published online: 26 MAR 2007
- Received 9 October 2006, revised 9 November 2006 and accepted for publication 22 November 2006
- Donor hepatectomy;
- living donation;
- living donor liver transplantation;
- MELD score;
- waiting time
Right lobe living donor liver transplantation (RLDLT) is not yet a fully accepted therapy for patients with end-stage liver failure in the Western hemisphere because of concerns about donor safety and inferior recipient outcomes. An outcome analysis from the time of listing for all adult patients who were listed for liver transplantation (LT) at our center was performed. From 2000 to 2006, 1091 patients were listed for LT. One hundred fifty-four patients (LRD; 14%) had suitable live donors and 153 (99%) underwent RLDLT. Of the remaining patients (DD/Waiting List; n = 937), 350 underwent deceased donor liver transplant (DDLT); 312 died or dropped off the waiting list; and 275 were still waiting at the time of this analysis. The LRD group had shorter mean waiting times (6.0 months vs. 9.8 months; p < 0.001). Although medical model for end-stage liver disease (MELD) scores were similar at the time of listing, MELD scores at LT were significantly higher in the DD/Waiting List group (15.4 vs. 19.5; p = 0.002). Patients in Group 1 had a survival advantage with RLDLT from the time of listing (1-year survival 90% vs. 80%; p < 0.001). To our knowledge, this is the first report to document a survival advantage at time of listing for RLDLT over DDLT.